PA
DFTX

Parallel Advisors’s Definium Therapeutics DFTX Stock Holding History

Parallel Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7K Buy
333
+101
+44% +$2.5K ﹤0.01% 2735
2026
Q1 		$4.4K Hold
232
– – ﹤0.01% 3082
2025
Q4 		$3.12K Hold
232
– – ﹤0.01% 3001
2025
Q3 		$2.74K Sell
232
-20
-8% -$187 ﹤0.01% 2970
2025
Q2 		$1.63K Buy
252
+233
+1,226% +$1.53K ﹤0.01% 3087
2025
Q1 		$111 Hold
19
– – ﹤0.01% 3436
2024
Q4 		$132 Sell
19
-700
-97% -$4.82K ﹤0.01% 3419
2024
Q3 		$4.09K Hold
719
– – ﹤0.01% 2679
2024
Q2 		$5.18K Buy
719
+700
+3,684% +$6.12K ﹤0.01% 2535
2024
Q1 		$179 Sell
19
-458
-96% -$2.61K ﹤0.01% 3161
2023
Q4 		$1.75K Hold
477
– – ﹤0.01% 2839
2023
Q3 		$1.49K Sell
477
-66
-12% -$271 ﹤0.01% 2895
2023
Q2 		$1.94K Hold
543
– – ﹤0.01% 2758
2023
Q1 		$1.72K Buy
543
+400
+280% +$1.33K ﹤0.01% 2817
2022
Q4 		$315 Hold
143
– – ﹤0.01% 3118
2022
Q3 		$1K Sell
143
-1,668
-92% -$16K ﹤0.01% 2958
2022
Q2 		$17K Buy
+1,811
New +$22.9K ﹤0.01% 1736

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Parallel Advisors's DFTX Position: Q2 2026 in Review

Parallel Advisors increased its Definium Therapeutics (DFTX) stake by 44% in Q2 2026, buying an estimated $2.5K and bringing the position to 333 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

Parallel Advisors first reported a position in DFTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $17K in Q2 2022. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Parallel Advisors held 333 shares of Definium Therapeutics worth $15.7K as of Q2 2026.
  • Parallel Advisors bought 101 Definium Therapeutics shares in Q2 2026, an estimated $2.5K.
  • Definium Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2735 holding.
  • Parallel Advisors first reported a position in Definium Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Parallel Advisors's Definium Therapeutics position peaked at $17K in Q2 2022.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.